Use

This test is indicated to identify individuals of Ashkenazi Jewish ancestry, and/or those with a personal or family history of breast, ovarian, pancreatic, or high‑grade prostate cancer, who have an increased risk for hereditary breast and ovarian cancer syndrome. Two major founder mutations in BRCA1 and one in BRCA2 — common in this population — are targeted, enabling targeted risk assessment and appropriate genetic counseling and management. Informed consent and genetic counseling are strongly recommended prior to testing. Quest suggests that if broader ancestry or clinical criteria are present, more comprehensive testing may be warranted.